M iao Yongjun is the founder and chairman of Autobio Diagnostics, a leading Chinese company specializing in clinical diagnostic products. Founded in 1998 and headquartered in Zhengzhou, the company develops and manufactures immunoassay and microbiology testing instruments and reagents. Miao has focused heavily on research and development, helping Autobio become a key supplier to hospitals and medical labs across China.

The company went public on the Shanghai Stock Exchange in 2016. Miao's leadership has driven Autobio's growth in the competitive in vitro diagnostics (IVD) market, challenging international giants with high-quality, cost-effective solutions. He continues to steer the company's strategy as it expands its automated testing capabilities.